Billiontoone (NASDAQ:BLLN) Insider Oguzhan Atay Sells 26,250 Shares

Billiontoone, Inc. (NASDAQ:BLLN) insider Oguzhan Atay sold 26,250 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $97.66, for a total value of $2,563,575.00. Following the completion of the transaction, the insider owned 20,000 shares in the company, valued at $1,953,200. This represents a 56.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Monday, June 8th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total value of $1,227,750.00.

Billiontoone Stock Down 3.1%

Shares of BLLN traded down $3.13 during trading hours on Wednesday, reaching $99.26. The company’s stock had a trading volume of 1,040,614 shares, compared to its average volume of 694,048. The company has a 50 day moving average of $87.26 and a two-hundred day moving average of $88.18. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $138.70. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. The company’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.39) EPS. On average, analysts predict that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Institutional Investors Weigh In On Billiontoone

Large investors have recently added to or reduced their stakes in the stock. Rossby Financial LCC bought a new stake in Billiontoone during the fourth quarter worth approximately $25,000. Wells Fargo & Company MN bought a new stake in Billiontoone during the fourth quarter worth approximately $76,000. Smartleaf Asset Management LLC bought a new stake in Billiontoone during the fourth quarter worth approximately $80,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Billiontoone in the fourth quarter valued at approximately $82,000. Finally, Renaissance Capital LLC bought a new stake in shares of Billiontoone in the fourth quarter valued at approximately $201,000.

Analyst Ratings Changes

BLLN has been the subject of several recent research reports. Wells Fargo & Company lowered their price target on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Weiss Ratings cut Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 5th. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. BTIG Research decreased their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. upped their target price on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $125.29.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.